Company Changes (4/04)
You may also be interested in...
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
In a pair of guidance documents the US agency explains clearance options and its enforcement policy for sponsors of devices used to reduce contaminants in COVID-19 masks and respirators.